Bayview Pharmacy is pleased to offer a compounded formulation of Estradiol 9 Mcg/Estriol 0.5 mg Vaginal Suppository. This solid dosage form is designed to be inserted into the vagina, where it dissolves or melts to release the medication. The purpose of this method is to allow for local or systemic absorption of the medication, providing direct relief to the affected area.

This particular formulation is primarily used for the treatment of conditions such as atrophic vaginitis, menopausal symptoms, dyspareunia, vulvovaginal atrophy, and genitourinary syndrome of menopause. These conditions often result in uncomfortable symptoms like vaginal dryness, itching, burning, and pain during intercourse. The combination of estradiol and estriol in this formulation works to restore the natural balance of hormones in the body, providing relief from these symptoms.

The suppository form of delivery ensures that the medication is absorbed directly into the bloodstream, allowing for a more efficient and effective treatment. This method of delivery is not only effective but also safe and well-tolerated by most patients. It can provide quick and effective relief from the uncomfortable symptoms associated with these conditions.

If you have any questions about this compounded formulation of Estradiol 9 Mcg/Estriol 0.5 mg Vaginal Suppository, or if you would like to learn more about how it can help treat your condition, please do not hesitate to reach out to us at Bayview Pharmacy. Our team is dedicated to helping you find the best treatment option for your needs.

Estradiol 9 Mcg/Estriol 0.5 mg Vaginal Suppository is a compounded formulation designed for the treatment of atrophic vaginitis, menopausal symptoms, dyspareunia, vulvovaginal atrophy, and genitourinary syndrome of menopause. This medication is inserted into the vagina, where it dissolves to release the active ingredients for local absorption.

It is important to note that this formulation is contraindicated in patients with known hypersensitivity to estradiol or estriol. Additionally, estrogen therapy should not be used in women with a range of conditions including active thrombophlebitis or thromboembolic disorders, a history of endometrial cancer or endometrial hyperplasia, active or past history of breast cancer, active liver disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected estrogen-dependent neoplasia, active deep vein thrombosis, pulmonary embolism, or history of these conditions, known or suspected hypercalcemia, and known or suspected hypersensitivity to any of the ingredients in the formulation.

Estrogen therapy may increase the risk of several health conditions including endometrial hyperplasia, endometrial cancer, breast cancer, thromboembolic disorders, stroke, coronary artery disease, hypercalcemia, liver disease, gallbladder disease, hypertension, hypertriglyceridemia, hypercholesterolemia, dementia, cataracts, endometriosis, ovarian cancer, uterine fibroids, deep vein thrombosis, and pulmonary embolism. Therefore, patients should be closely monitored for signs and symptoms of these conditions while undergoing treatment.

If you have any questions about the use of Estradiol 9 Mcg/Estriol 0.5 mg Vaginal Suppository for the treatment of atrophic vaginitis, menopausal symptoms, dyspareunia, vulvovaginal atrophy, and genitourinary syndrome of menopause, please do not hesitate to reach out for further information.

Estradiol 9 Mcg/Estriol 0.5 mg Vaginal Suppository is a specially compounded medication primarily used to alleviate a range of conditions associated with menopause. These conditions include atrophic vaginitis, menopausal symptoms, dyspareunia, vulvovaginal atrophy, and genitourinary syndrome of menopause. The suppository is designed to be inserted into the vagina, where it gradually dissolves to release the medication over a sustained period.

The medication contains two key active ingredients: estradiol and estriol. Estradiol works to reduce inflammation and restore the natural hormonal balance within the body, which can be disrupted during menopause. Estriol, on the other hand, is effective in reducing common menopausal symptoms such as hot flashes, night sweats, and vaginal dryness.

The combination of estradiol and estriol in this formulation not only helps to manage the symptoms of menopause but also reduces the risk of developing complications associated with this stage of life. These complications can include osteoporosis and urinary tract infections. The suppository is typically used once daily for a period of up to 12 weeks. It can also be used in conjunction with other treatments, such as hormone replacement therapy, to provide comprehensive management of menopausal symptoms.

Patients should be aware that the use of this suppository may cause some initial irritation or a burning sensation upon insertion. If these symptoms persist, it is recommended to contact a healthcare provider for advice. This formulation is designed to provide targeted relief for menopausal symptoms, and any questions or concerns about its use or effects should be directed to a healthcare professional.

This compounded formulation of Estradiol 9 Mcg/Estriol 0.5 mg Vaginal Suppository is a versatile treatment option for a variety of conditions. It is primarily used to alleviate symptoms such as vaginal dryness, itching, and burning, which are common issues experienced by postmenopausal women. Beyond these applications, this formulation also serves as a preventive measure against recurrent urinary tract infections in postmenopausal women, providing a localised treatment option that targets the issue at its source.

Furthermore, this Estradiol/Estriol combination can be used as a proactive measure to reduce the risk of osteoporosis in postmenopausal women. Osteoporosis is a condition that weakens bones, making them fragile and more likely to break. By using this formulation, postmenopausal women can potentially strengthen their bone health and reduce the risk of fractures.

Another significant benefit of this formulation is its potential to reduce the risk of endometrial hyperplasia in postmenopausal women who are not taking progestins. Endometrial hyperplasia is a condition that thickens the lining of the uterus and can lead to cancer. This formulation can help to regulate the thickness of the endometrial lining, thereby reducing the risk of hyperplasia.

Lastly, this formulation may also be used to reduce the risk of breast cancer in postmenopausal women. Breast cancer is one of the most common cancers among women, and this formulation provides a potential preventive measure. If you have any questions about the use of this formulation for any of these conditions, please do not hesitate to reach out for more information.